GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

 
• By Sue Sutter

Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.

Oncologic Drugs Advisry Committee Meeting has technical difficulties
FDA had to restart the ODAC meeting two hours after it originally began due to technical problems. • Source: Screen shot

More from United States

More from North America